ArticleEmerging infectious diseases2009
Increase in pneumococcus macrolide resistance, United States.
Article in Emerging infectious diseases, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed.
- Reporting macrolide-resistantJournal of clinical microbiology · 2026Review
- Article
- Comparison of antimicrobial resistance genes on the ocular surface of patients with corneal infections in California and Malawi.International health · 2025Article
- Antibiotic resistance ofJournal of water and health · 2024Article
- Antibiotic prescription for outpatients with influenza and subsequent hospitalisation: A cohort study using insurance data.Influenza and other respiratory viruses · 2023Article
- Antibiotic Prescription Patterns in the Paediatric Primary Care Setting before and after the COVID-19 Pandemic in Italy: An Analysis Using the AWaRe Metrics.Antibiotics (Basel, Switzerland) · 2022Article
- Macrolide Treatment Failure due to Drug-Drug Interactions: Real-World Evidence to Evaluate a Pharmacological Hypothesis.Pharmaceutics · 2022Article
- A Multicenter Evaluation of the US Prevalence and Regional Variation in Macrolide-ResistantOpen forum infectious diseases · 2021Article
- Biographical Feature: Stephen G. Jenkins, Ph.D., D(ABMM), F(AAM).Journal of clinical microbiology · 2019Article
- Antimicrobial Stewardship in the Emergency Department.Emergency medicine clinics of North America · 2018Review
- Article
- Macrolide-Resistant Mycoplasma pneumoniae Infection, Japan, 2008-2015.Emerging infectious diseases · 2017Article
- Article
- Risk Factors for Outpatient Use of Antibiotics in Children with Acute Respiratory Illnesses.Southern medical journal · 2017Observational
- Resistance to Macrolide Antibiotics in Public Health Pathogens.Cold Spring Harbor perspectives in medicine · 2016Review
- Emerging non-PCV13 serotypes of noninvasive Streptococcus pneumoniae with macrolide resistance genes in northern Japan.New microbes and new infections · 2016Article
- Mobile elements and chromosomal changes associated with MLS resistance phenotypes of invasive pneumococci recovered in the United States.Microbial drug resistance (Larchmont, N.Y.) · 2015Article
- Antibiotic prescribing for respiratory infections at retail clinics, physician practices, and emergency departments.The American journal of managed care · 2015Article
- Long-term macrolide therapy in chronic obstructive pulmonary disease.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2014Review
- Gradenigo syndrome: unusual consequence of otitis media.Case reports in neurology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During year 6 (2005-2006) of the Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin surveillance study, 6,747 Streptococcus pneumoniae isolates were collected at 119 centers. The susceptibility of these isolates to macrolides was compared with data from previous years. Macrolide resistance increased significantly in year 6 (35.3%) from the stable rate of approximately 30% for the previous 3 years (p<0.0001). Macrolide resistance increased in all regions of the United States and for all patient age groups. Rates were highest in the south and for children 0-2 years of age. Lower-level efflux [mef(A)]-mediated macrolide resistance decreased in prevalence to approximately 50%, and highly resistant [erm(B) + mef(A)] strains increased to 25%. Telithromycin and levofloxacin susceptibility rates were >99% and >98%, respectively, irrespective of genotype. Pneumococcal macrolide resistance in the United States showed its first significant increase since 2000. High-level macrolide resistance is also increasing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.